These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3937253)

  • 1. [Lymphocyte T population in hemophilia A and its relation with factor VIII therapy and the presence of HBsAg or anti-F.VIII:C inhibitors].
    Aznar JA; Carbonell F; Jorquera JI; Carmona E; Sánchez-Cuenca JM; Trénor A; de Andrés-Medina R; González-Molina A
    Sangre (Barc); 1985; 30(5):821-30. PubMed ID: 3937253
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological studies of haemophilic patients with inhibitors treated with Factor VIII concentrates in a protocol to induce immunotolerance.
    Aznar JA; Jorquera JI; Carbonell F; Sánchez-Cuenca JM; Trenor A; De Andrés Medina R; Carmona E; González-Molina A
    Thromb Haemost; 1984 Oct; 52(2):212-3. PubMed ID: 6441305
    [No Abstract]   [Full Text] [Related]  

  • 3. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST; Addiego JE; Reason DC; Lucas AH
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphocyte subpopulations in hemophilia A and B].
    Ollero M; Leal M; Wichman I; García M; Muñoz J; Miranda ML; Jiménez JM; Núñez A; Pascual A; Lissen E
    Med Clin (Barc); 1984 Oct; 83(12):479-81. PubMed ID: 6439957
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological alterations in haemophiliacs treated with lyophilized Factor VIII cryoprecipitate from volunteer donors.
    Ceuppens JL; Vermylen J; Colaert J; Desmyter J; Gautama K; Stevens E; The AL; Vanham G; Vermylen C; Verstraete M
    Thromb Haemost; 1984 Apr; 51(2):207-11. PubMed ID: 6429883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal T-lymphocyte subsets in hemophilia: relation to HLA proteins in plasma products.
    Lee CA; Kernoff PB; Karayiannis P; Waters J; Thomas HC
    N Engl J Med; 1984 Apr; 310(16):1058. PubMed ID: 6424010
    [No Abstract]   [Full Text] [Related]  

  • 8. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suggestions for the management of factor VIII inhibitors.
    Rubinger M; Rivard GE; Teitel J; Walker H;
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors.
    Ingerslev J; Wallevik K
    Ann Hematol; 1991 Sep; 63(3):152-4. PubMed ID: 1932291
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunobiology of inhibitor development in hemophilia A.
    Fijnvandraat K; Bril WS; Voorberg J
    Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
    Nilsson IM; Hedner U; Holmberg L
    Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.